CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein Early Evidence of CFT1946 Monotherapy Anti-Tumor Activity in Patients Who Have Progressed on or After BRAF Inhibitor Therapies; Majority of Patients Demonstrated Tumor Reduction Across V600 Mutation Types CFT1946 Global Phase 1 Trial Continues to Enroll; Monotherapy and Combination Expansion Cohorts Advancing With Additional Dat ...

Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity Investor Webcast to be Held Friday, September 13, 2024 at 12:00 pm ET WATERTOWN, Mass., Sept. 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the abstract sharing clinical data from its ongoing Phase 1 clinical trial of CFT1946, a novel BiDAC™ degrader, ...

WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service. "We are excited to welcome Steve to the Board of Direc ...

WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor conferences. Fireside Chat Details: Event: Wells Fargo Healthcare Conference taking place in Boston, MA Date/Time: September 5, 2024 at 8:45 AM ET Event: 2024 Cantor Global Healthcare Conference taking place in New ...

Company Performance - C4 Therapeutics reported a quarterly loss of $0.26 per share, better than the Zacks Consensus Estimate of a loss of $0.37, and improved from a loss of $0.73 per share a year ago, representing an earnings surprise of 29.73% [1] - The company posted revenues of $12.01 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 74.51%, compared to revenues of $2.66 million in the same quarter last year [2] - Over the last four quarters, C4 Therapeutics has exceeded consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - C4 Therapeutics shares have increased approximately 18.6% since the beginning of the year, outperforming the S&P 500's gain of 15.8% [3] - The current Zacks Rank for C4 Therapeutics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.37 on revenues of $9.4 million, and for the current fiscal year, it is -$1.56 on revenues of $26.48 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where C4 Therapeutics operates, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Se ...

Preliminary Monotherapy Data from the Ongoing CFT1946 Phase 1 Trial in BRAF V600X Solid Tumors to be Presented at ESMO Congress 2024; Initiated Monotherapy Expansion Cohort in Melanoma and Combination Cohort with Cetuximab in Colorectal Cancer Cemsidomide Phase 1 Trial in Multiple Myeloma and non-Hodgkin's Lymphoma Continues to Progress through Dose Escalation; Data on Track for Q4 2024 Cash, Cash Equivalents and Marketable Securities of $295.7 million as of June 30, 2024; Expected to Provide Runway into 20 ...

This company is expected to post quarterly loss of $0.37 per share in its upcoming report, which represents a year-over-year change of +49.3%. Revenues are expected to be $6.88 million, up 158.7% from the year-ago quarter. C4 Therapeutics, Inc. (CCCC) shares rallied 13.7% in the last trading session to close at $7.38. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 56.8% gain over the past four weeks. The sud ...

Details of the presentation are as follows: About C4 Therapeutics Contacts: WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentati ...

WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking ...